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Background: Endothelin receptor antagonists (ERA) improve the
prognosis of patients with pulmonary arterial hypertension (PAH).
However, only limited data are available on the effect of treatment
with the ERA bosentan on exercise capacity assessed with cardio-
pulmonary exercise testing (CPX) in patients with PAH or inoperable
chronic thromboembolic pulmonary hypertension (CTEPH). Purpose:
To investigate the effect of the oral, dual-ERA bosentan on exercise
capacity in patients with PAH or inoperable CTEPH by means of CPX.
Methods: Fifteen consecutive PAH (mean age, 47 ± 21 years) and 9
consecutive inoperable CTEPH patients (mean age, 49 ± 12 years)
with World Health Organization Functional Class II to IV were
treated with bosentan. All patients underwent cardiac catheteriza-
tion, echocardiography, and CPX at baseline. CPX was performed
both prior to initiation of bosentan therapy and after 6 months.
Results: In PAH patients, peak VO2 signiﬁcantly increased from
13.8 ± 6.8 mL/kg/min at baseline to 16.8 ± 7.2 mL/kg/min after
6 months (P b 0.01). Similarly, VE/VCO2 slope also signiﬁcantly
decreased from 56.8 ± 22.5 to 48.9 ± 17.5 (P b 0.05). However, in
CTEPH patients, there were no signiﬁcant differences in peak VO2 or
VE/VCO2 slope between the before and after bosentan therapy
values (P = 0.35, P = 0.67, respectively). The medication was well
tolerated by all patients, and there was no evidence of drug-related
liver dysfunction. Conclusions: Bosentan therapy improves exercise
capacity in patients with PAH within a relatively short period.
However, the effect is not seen in patients with CTEPH.
doi:10.1016/j.lfs.2013.12.155
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Background: Bosentan and sildenaﬁl are often administered togeth-
er for the treatment of PAH. Bosentan is a known inducer of CYP3A4 in
chronic use and therefore, the plasma concentration of sildenaﬁl is
decreased almost by half when co-administered. In the course of daily
life, patients tend to take these medicines at the same time in the
morning and the evening. We investigated how the plasma concentra-
tion of sildenaﬁl changed when bosentan/sildenaﬁl was taken before-
hand with the other. Methods: A randomized, open-label crossover
study was conducted in PAH patients of WHO functional class III,
who chronically received both bosentan and sildenaﬁl. Patients were
randomly assigned to either Pattern 1 or 2, both of which consisted of
three phases as follows; phase S: patients take sildenaﬁl 3 h prior to
bosentan, phase B: patients take bosentan 3 h prior to sildenaﬁl, and
phase C: patients take sildenaﬁl and bosentan simultaneously (control).
We collected blood samples on the last day of each phase andmeasured
the plasma concentration of sildenaﬁl using liquid chromatography-
tandem mass spectrometry. Results: Six patients entered the study. In
sildenaﬁl Cmax, phase S was 72.9 ± 40.9 (ng/ml, mean± S.D) and it
was signiﬁcantly lower than phase C (P= 0.0215). Phase B was 99.6 ±
33.9 with no signiﬁcant difference with phase C (P= 0.6173). In
sildenaﬁl AUC0-8, phase S was 108.2 ± 126.4 (h/ng/ml, mean± S.D)
and phase B was 240.7 ± 121.8. Neither phase proved signiﬁcant
difference with that of phase C (203.5 ± 81.3, P = 0.3213 and 0.1999,
respectively). Conclusion: It is indicated that there is a short-term drug
interaction between bosentan and sildenaﬁl which may be relevant to
CYP3A4 metabolism.
doi:10.1016/j.lfs.2013.12.156
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Rationale: A novel dual ETA/ETB receptor antagonist, macitentan,
has been reported to signiﬁcantly reduce morbidity and mortality in
patients with pulmonary arterial hypertension (PAH) (SERAPHIN
study). However, the underlying mechanisms warrant further
preclinical investigations. We have established a rat model of PAH,
which develops severe pulmonary hypertension (PH) with occlusive
pulmonary arteriopathy indistinguishable from that in PAH patients.
This study investigated the effects of macitentan on hemodynamics
and histopathology in the rat model with established severe PAH.
Method and results: Rats received a single subcutaneous injection of
20 mg/kg SU5416, a VEGF blocker, and then exposed to 3-week
hypoxia (10% O2) followed by 5 weeks of normoxia. Eight weeks
after the SU5416 injection, in comparison with normal rats, all rats
developed severe PH (RV systolic pressure: 23 ± 6 vs. 102 ± 15mmHg,
n = 4 or 5 for each, p b 0.001) with RV hypertrophy (the mass ratio of
RV to LV pulse septum: 0.23 ± 0.01 vs. 0.77 ± 0.05, p b 0.001). Five-
week treatmentwithmacitentan (30 mg/kg/day, orally, fromweek 3 to
8) signiﬁcantly reduced RV systolic pressure (41 ± 5 mmHg, n = 6,
P b 0.05) and hypertrophy (0.36 ± 0.03, n = 7, P b 0.005) without
decreasing cardiac output. Also, macitentan signiﬁcantly attenuated
the medial wall thickness and complex occlusive lesions in PAH
rats by histological examination. Conclusion: Chronic treatment with
macitentan markedly hemodynamically and histopathologically im-
proved PAH in SU5416/hypoxia/normoxia-exposed rats. The improve-
ment of arteriopathy may in part contribute to the beneﬁcial effects of
macitentan on PH.
doi:10.1016/j.lfs.2013.12.157
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We showed previously that ambrisentan, a selective endothelin type
A receptor antagonist, and tadalaﬁl, a PDE5 inhibitor, act synergistically
to relax endothelin-constricted pulmonary arteries (Liang et al. Hyper-
tension 2012; 59: 705-11). To conﬁrm these ﬁndings in an in-vivomodel
of PAH, we investigated the effect of ambrisentan and tadalaﬁl in
combination on hypoxia-induced PAH in rats. Upon exposure to hypoxia
(10% O2), male SD rats were dosed with vehicle, ambrisentan (1 mg/kg,
q.d.), tadalaﬁl (10 mg/kg, q.d.) or the combination via oral gavage for
3 weeks. Three weeks of exposure of rats to hypoxia increased mean
pulmonary arterial pressure (mPAP) from 10.8 &plusmn0.7 mmHg
(normoxic, mean &plusmn SEM, n= 8) to 23.9 &plusmn1.3 mmHg
(hypoxic, n = 12, p b 0.01 vs normoxic). Teatments with ambrisentan,
tadalaﬁl and the combination reducedmPAP to 20.1 &plusmn0.8 mmHg
(n= 12, p b 0.05 vs hypoxic), 20.8 &plusmn1.2 mmHg (n= 11,
p b 0.05 vs hypoxic) and 15.9 &plusmn1.0 mmHg (n= 12, p b 0.01 vs
hypoxic), respectively. Chronic exposure of rats to hypoxia also increased
the ratio of right ventricle weight/ left ventricle weight (RV/LV) from
0.326 &plusmn0.013 (normoxic, n = 8) to 0.602 &plusmn0.019 (hyp-
oxic, n = 12, p b 0.01 vs normoxic). The ratios of RV/LV from hypoxic
rats dosed with ambrisentan, tadalaﬁl and the combination were
decreased to 0.527 &plusmn0.014 (n= 12, p b 0.05 vs hypoxic),
0.531 &plusmn0.016 (n= 11, p b 0.05 vs hypoxic) and 0.430 &plusmn
0.017 (p b 0.01 vs hypoxic). Consistent with the in-vitro pulmonary
artery data, the combination of ambrisentan and tadalaﬁl caused a
greater effect than each drug alone or the calculated sum of the
individual effects of each drug, suggesting that ambrisentan and tadalaﬁl
synergistically attenuate hypoxia-induced PAH in rats.
doi:10.1016/j.lfs.2013.12.158
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Objectives: The currently ongoing DETECT study, a two-stage,
prospective, observational, cohort study in systemic scleroderma (SSc)
patients to evaluate screening tests and the incidence of pulmonary
arterial hypertension (PAH) and pulmonary hypertension, is
attempting to reﬁne the screening process in pulmonary artery
hypertension associated with SSc. We adopted the same multiple
screening tests forced vital capacity [% predicted]/DLCO [% predicted];
current/past telangiectasias; anti-centromere antibody; N-terminal
pro-brain natriuretic peptide; uric acid; right axis deviation on
electrocardiography) in patients with SSc in our hospital to evaluate
its Method: Date from 21 SSC patients, who had undergone right heart
catheterization from 2009 to 2012 in our hospital, were retrospectively
analyzed.We compared the result of DETECT screening system tomean
pulmonary artery pressure assessed by right heart catheterization.
Results: Seventeen SSc patients (80.9%) were categorized as candidates
to referral to right heart catheterization in this study. Overall sensitivity
was 100% and speciﬁcity was 25%. Conclusion: According to the 2012
American College of Rheumatology Annual Meeting, DETECT algorithm
was announced that its sensitivity was 96% and speciﬁcity was 48%.
Therefore, our results indicated that DETECT algorithm had the
possibility to overestimate the risk of PAH in SSc patients.
doi:10.1016/j.lfs.2013.12.159
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There is increased risk of pulmonary hypertension (PH) in
patients with Atrial Septal Defect (ASD), although the factors
associated have not been clearly deﬁned. Endothelin-1 (ET-1), a
potent vasoconstrictor derived mainly from pulmonary endothelium,
has been reported to be elevated in PH associated with congenital
heart defect (CHD). However, studies about CHD-related PH included
only a small number of ASD-patients and most of them were
performed in children. In this study, we aim to measure the
circulating ET-1 level in adult patients with uncorrected ASD
complicated by severe pulmonary hypertension. Fifty-two newly
diagnosed ASD patients were participating in this study, aged 20–
79 years old. Measurements of RVSP, characteristics of ASD, remod-
eling RV were performed using TTE and TEE. The hemodynamic
measurement by echo showed signiﬁcant correlation with right
heart catheterization (r = 0.8;p b 0.0001). Peripheral blood was
withdrawn from brachialis vein and circulating ET-1 was measured
using ELISA. Severe PH were deﬁned as RVSP N 60 mmHg. The severe
PH group (n = 25) was conﬁrmed by larger RA diameter, larger RV
diameter, reduced RV systolic function, and higher tricuspid valve
gradient as compared to non-severe PH group (n = 27) (47.6 ± 1.47
vs. 41.2 ± 1.24 mm; p b 0.01; 48.6 ± 1.16 vs. 41.2 ± 1.29 mm;
p b 0.001; 21.9 ± 1.01 vs. 25.9 ± 1.45 mm; p b 0.0001; 92 ± 5.5 vs.
33.7 ± 1.88 mmHg; p b 0.0001; respectively). There were no differ-
ences of age, diameter of the defect, and pulmonary ﬂow ratio in the
severe PH group. Interestingly, the circulating plasma ET-1 level was
signiﬁcantly lower in the severe group (6.3 ± 0.48 vs. 4.7 ± 0.32 pg/dl;
p b 0.01). In conclusion, we reported lower circulating plasma ET-1 in
ASD patients with severe PH. Further study should be performed to
elucidate the ET-1 level in pulmonary circulation in this disease.
doi:10.1016/j.lfs.2013.12.160
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Background: Endothelin receptor antagonist (ERA) is recom-
mended for treatment of pulmonary arterial hypertension (PAH).
However, recommendation is based on reports of monotherapy.
Method: We examined consecutive 112 patients diagnosed with
Group 1 and 1' PAHwho visited 14 afﬁliated hospitals from July 2006
to January 2013. The difference in mortality between monotherapy
group and combination therapy group (ERA and other PAH drugs)
was compared. Results: There were 41 idiopathic, 43 collagen
tissue disease, 24 congenial heart disease and 4 other types of PAH.
Mean age was 52.2 years old, female 66.1%, WHO Functional
Class1 5.6%, 2 31.5%, 3 53.9%, 4 9.0%, BNP 128 (49.3–406.5) pg/mL,
cardiac index 3.4 ± 1.6 (L/kg/m2), mean pulmonary arterial pressure
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